These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 29750310)

  • 1. Mina53 nuclear localization is an important indicator of prognosis in patients with colorectal cancer after adjuvant chemotherapy.
    Fujino S; Kinugasa T; Sudo T; Mizobe T; Yoshida T; Yoshida N; Ohchi T; Tajiri K; Yuge K; Nagasu S; Katagiri M; Akagi Y
    Oncol Rep; 2018 Jul; 40(1):101-110. PubMed ID: 29750310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PLA2 (group IIA phospholipase A2) as a prognostic determinant in stage II colorectal carcinoma.
    Buhmeida A; Bendardaf R; Hilska M; Laine J; Collan Y; Laato M; Syrjänen K; Pyrhönen S
    Ann Oncol; 2009 Jul; 20(7):1230-5. PubMed ID: 19276398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
    Stanisavljević L; Myklebust MP; Leh S; Dahl O
    Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of the myc target gene Mina53 in advanced renal cell carcinoma.
    Ishizaki H; Yano H; Tsuneoka M; Ogasawara S; Akiba J; Nishida N; Kojiro S; Fukahori S; Moriya F; Matsuoka K; Kojiro M
    Pathol Int; 2007 Oct; 57(10):672-80. PubMed ID: 17803656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Predictive value of combination detection of tissue Pgp1 expression and preoperative serum CEA level for colorectal cancer].
    Wu F; Chen L; Wu W; Jiang B; Su X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Apr; 20(4):443-449. PubMed ID: 28440527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer.
    Bruun J; Sveen A; Barros R; Eide PW; Eilertsen I; Kolberg M; Pellinen T; David L; Svindland A; Kallioniemi O; Guren MG; Nesbakken A; Almeida R; Lothe RA
    Mol Oncol; 2018 Sep; 12(9):1639-1655. PubMed ID: 29900672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Dose Reductions, Delays Between Chemotherapy Cycles, and/or Shorter Courses of Adjuvant Chemotherapy in Stage II and III Colorectal Cancer Patients: a Single-Center Retrospective Study.
    Sgouros J; Aravantinos G; Kouvatseas G; Rapti A; Stamoulis G; Bisvikis A; Res H; Samantas E
    J Gastrointest Cancer; 2015 Dec; 46(4):343-9. PubMed ID: 26143067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymph Node Ratio as a Risk Factor for Recurrence After Adjuvant Chemotherapy in Stage III Colorectal Cancer.
    Ooki A; Akagi K; Yatsuoka T; Asayama M; Hara H; Nishimura Y; Katoh H; Yamashita K; Watanabe M; Yamaguchi K
    J Gastrointest Surg; 2017 May; 21(5):867-878. PubMed ID: 28251467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of carcinoembryonic antigen and carbohydrate antigen 19-9 in stage IV colorectal cancer patients after R0 resection.
    Abe S; Kawai K; Ishihara S; Nozawa H; Hata K; Kiyomatsu T; Tanaka T; Watanabe T
    J Surg Res; 2016 Oct; 205(2):384-392. PubMed ID: 27664887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-chemotherapeutic CEA and CA19-9 are prognostic factors in patients with colorectal liver metastases treated with hepatic resection after oxaliplatin-based chemotherapy.
    Sakamoto Y; Miyamoto Y; Beppu T; Nitta H; Imai K; Hayashi H; Baba Y; Yoshida N; Chikamoto A; Baba H
    Anticancer Res; 2015 Apr; 35(4):2359-68. PubMed ID: 25862901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential clinical benefits of 5-fluorouracil-based adjuvant chemotherapy for patients with stage III colorectal cancer according to CD133 expression status.
    Shikina A; Shinto E; Hashiguchi Y; Ueno H; Naito Y; Okamoto K; Kubo T; Fukazawa S; Yamamoto J; Hase K
    Jpn J Clin Oncol; 2014 Jan; 44(1):42-8. PubMed ID: 24244031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
    Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
    J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRT17 as a prognostic biomarker for stage II colorectal cancer.
    Ujiie D; Okayama H; Saito K; Ashizawa M; Thar Min AK; Endo E; Kase K; Yamada L; Kikuchi T; Hanayama H; Fujita S; Sakamoto W; Endo H; Saito M; Mimura K; Saze Z; Momma T; Ohki S; Kono K
    Carcinogenesis; 2020 Jul; 41(5):591-599. PubMed ID: 31754689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
    JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
    Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G
    Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative serum carcinoembryonic antigen, carbohydrate antigen19-9 and carbohydrate antigen 125 as prognostic factors for recurrence-free survival in colorectal cancer.
    Yang XQ; Chen C; Wang FB; Peng CW; Li Y
    Asian Pac J Cancer Prev; 2011; 12(5):1251-6. PubMed ID: 21875276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefit of Adjuvant Chemotherapy After Curative Resection of Lung Metastasis in Colorectal Cancer.
    Park HS; Jung M; Shin SJ; Heo SJ; Kim CG; Lee MG; Beom SH; Lee CY; Lee JG; Kim DJ; Ahn JB
    Ann Surg Oncol; 2016 Mar; 23(3):928-35. PubMed ID: 26514121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer.
    Turan N; Benekli M; Koca D; Ustaalioglu BO; Dane F; Ozdemir N; Ulas A; Oztop I; Gumus M; Ozturk MA; Berk V; Kucukoner M; Uner A; Balakan O; Helvaci K; Ozkan S; Yilmaz U; Buyukberber S;
    Oncology; 2013; 84(1):14-21. PubMed ID: 23076023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological Factors Associated with Recurrence and Prognosis after R0 Resection for Stage IV Colorectal Cancer with Peritoneal Metastasis.
    Sato H; Kotake K; Sugihara K; Takahashi H; Maeda K; Uyama I;
    Dig Surg; 2016; 33(5):382-91. PubMed ID: 27119565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prognostic mutation panel for predicting cancer recurrence in stages II and III colorectal cancer.
    Sho S; Court CM; Winograd P; Russell MM; Tomlinson JS
    J Surg Oncol; 2017 Dec; 116(8):996-1004. PubMed ID: 28767131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.